200 related articles for article (PubMed ID: 3874738)
1. The estimation of circulating immune complexes, C3d, and anti-ds-DNA-antibody serum levels in the monitoring of therapeutic plasmapheresis in a patient with systemic lupus erythematosus. A case report.
Krapf F; Manger B; Koch B; Kraulledat P; Kalden JR
Clin Exp Rheumatol; 1985; 3(2):159-62. PubMed ID: 3874738
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic plasmapheresis in systemic lupus erythematosus. Effect on immune complexes and antibodies to DNA.
Jones JV; Robinson MF; Parciany RK; Layfer LF; McLeod B
Arthritis Rheum; 1981 Sep; 24(9):1113-20. PubMed ID: 6975635
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibodies against complement 3 neoantigens for detection of immune complexes and complement activation. Relationship between immune complex levels, state of C3, and numbers of receptors for C3b.
Aguado MT; Lambris JD; Tsokos GC; Burger R; Bitter-Suermann D; Tamerius JD; Dixon FJ; Theofilopoulos AN
J Clin Invest; 1985 Oct; 76(4):1418-26. PubMed ID: 2932466
[TBL] [Abstract][Full Text] [Related]
4. Correlation of C3d fixing circulating immune complexes with disease activity and clinical parameters in patients with systemic lupus erythematosus.
Sekita K; Doi T; Muso E; Yoshida H; Kanatsu K; Hamashima Y
Clin Exp Immunol; 1984 Mar; 55(3):487-94. PubMed ID: 6608422
[TBL] [Abstract][Full Text] [Related]
5. Evidence for a therapeutic effect of plasmapheresis in patients with systemic lupus erythematosus.
Jones JV; Cumming RH; Bacon PA; Evers J; Fraser ID; Bothamley J; Tribe CR; Davis P; Hughes GR
Q J Med; 1979 Oct; 48(192):555-76. PubMed ID: 317156
[TBL] [Abstract][Full Text] [Related]
6. Relationship between anti-DNA antibodies complement consumption and circulating immune complexes in systemic lupus erythematosus.
Davis P; Cumming RH; Verrier-Jones J
Clin Exp Immunol; 1977 May; 28(2):226-32. PubMed ID: 301447
[TBL] [Abstract][Full Text] [Related]
7. Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus.
Sohrabian A; Parodis I; Carlströmer-Berthén N; Frodlund M; Jönsen A; Zickert A; Sjöwall C; Bengtsson AA; Gunnarsson I; Rönnelid J
Arthritis Res Ther; 2019 Nov; 21(1):259. PubMed ID: 31783909
[TBL] [Abstract][Full Text] [Related]
8. Plasmapheresis in the treatment of systemic lupus erythematosus.
Błaszczyk M; Chorzelski T; Daszyński J; Gaczkowski A; Jabłońska S; Beutner EH
Arch Immunol Ther Exp (Warsz); 1981; 29(6):769-72. PubMed ID: 6983871
[TBL] [Abstract][Full Text] [Related]
9. Correlation of disease activity with circulating immune complexes (C1qbA) and complement breakdown products (C3D) in patients with systemic lupus erythematosus. A prospective study.
Swaak AJ; Groenwold J; Hannema A; Hack CE
Rheumatol Int; 1985; 5(5):215-20. PubMed ID: 3877968
[TBL] [Abstract][Full Text] [Related]
10. [Relationship of renal histopathology to immunoglobulin classes and complement fixation of anti-native DNA antibodies and components of immune complexes in patients with systemic lupus erythematosus (author's transl)].
Hashimoto H; Utagawa Y; Yamagata J; Okada T; Shiokawa Y; Suzuki S; Tomiyama T
Ryumachi; 1981 Sep; 21(5):366-74. PubMed ID: 6977194
[No Abstract] [Full Text] [Related]
11. Immune complexes in the pericardial fluid in systemic lupus erythematosus.
Quismorio FP
Arch Intern Med; 1980 Jan; 140(1):112-4. PubMed ID: 6965447
[TBL] [Abstract][Full Text] [Related]
12. Detection and characterization of DNA-anti-DNA complexes in a patient with systemic lupus erythematosus.
Bruneau CD; Edmonds JP; Hughes GR; Aarden L
Clin Exp Immunol; 1977 Jun; 28(3):433-6. PubMed ID: 302166
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of plasma C3d and immune complex determinations in the assessment of disease activity of patients with rheumatoid arthritis, systemic lupus erythematosus, and spondylitis ancylopoetica.
Krauledat PB; Krapf FE; Manger B; Kalden JR
Rheumatol Int; 1985; 5(3):97-101. PubMed ID: 3892637
[TBL] [Abstract][Full Text] [Related]
14. Systemic lupus erythematosus glomerulonephritis in children.
Garin EH; Shulman ST; Donnelly WH; Richard GA
Paediatrician; 1981; 10(5-6):351-67. PubMed ID: 6460214
[TBL] [Abstract][Full Text] [Related]
15. Plasma concentrations of complement split product C3d and immune complexes after procainamide induced production of antinuclear antibodies.
Brandslund I; Ibsen HH; Klitgaard NA; Svehag SE; Simonsen E; Diederichsen H
Acta Med Scand; 1986; 220(5):431-5. PubMed ID: 3492864
[TBL] [Abstract][Full Text] [Related]
16. Serum amyloid P component-DNA complexes are decreased in systemic lupus erythematosus. inverse association with anti-dsDNA antibodies.
Voss A; Nielsen EH; Svehag SE; Junker P
J Rheumatol; 2008 Apr; 35(4):625-30. PubMed ID: 18278838
[TBL] [Abstract][Full Text] [Related]
17. Plasmapheresis in the management of acute systemic lupus erythematosus?
Jones JV; Cumming RH; Bucknall RC; Asplin CM
Lancet; 1976 Apr; 1(7962):709-11. PubMed ID: 56531
[TBL] [Abstract][Full Text] [Related]
18. Circulating immune complexes in systemic lupus erythematosus: a reappraisal of the solid phase C1q radioimmunoassay.
Woodroffe AJ; Nozza JM; Muller KD; McIntosh SL; Hale GM; Clarkson AR
J Clin Lab Immunol; 1988 May; 26(1):5-7. PubMed ID: 3263507
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of antinuclear antibodies in systemic lupus erythematosus.
Liu HW; Chi CY; Lin SF; Tsai JH; Chen CY
Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1981 Sep; 14(3):135-45. PubMed ID: 7026188
[TBL] [Abstract][Full Text] [Related]
20. Complement split product C3d as an indicator of disease activity in systemic lupus erythematosus.
Röther E; Lang B; Coldewey R; Hartung K; Peter HH
Clin Rheumatol; 1993 Mar; 12(1):31-5. PubMed ID: 8467609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
